Matignon Technologies
3 Avenue Matignon, Paris, Ile-de-France, 75008, France
Overview
Matignon Technologies is a euro 50 M closed-end venture capital fund dedicated to investments in unlisted innovative, early-stage companies specialized in high technologies with strong growth potential. The Fund invests as a minority shareholder with a stake comprised between euro 0.5 M and 3.0 M euro. Subscriptions were closed in September 2000 and the Fund has a lifespan of six years.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Venture Capital
Investment portfolio
- Arterial Remodeling Technologies
Participated · Equity · Sep 2010
Arterial Remodeling Technologies develops fully resorbable coronary polymer stents intended to promote natural remodeling of an injured artery after angioplasty. The technology is based on intellectual property originating from the Cleveland Clinic, CNRS (Montpellier) and Descartes University (Paris). The company is based in Noisy le Roi, France. On 21 September 2010 it closed an $8.5M new venture financing round. That financing brought the total capital raised by the company to date to $17M. Investors in the round included existing backers Matignon Technologies and Amundi Private Equity Funds and new partner InnoBio Fund (managed by CDC Entreprises).
- Nanobiotix
Participated · Series C · May 2010
Nanobiotix develops therapeutic products for cancer that leverage nanotechnologies, with its lead program focused on nanoXray therapeutics. The company is entering a first-in-man clinical study of nanoXray with IGR Institut Gustave Roussy for soft tissue sarcoma as the initial indication. It has built a portfolio of industrial and academic collaborations, including projects such as Sonodrug with Philips Research and a partnership with Biotech Corp in Malaysia. Nanobiotix plans to reinforce its scientific and development teams and resources to support clinical development. The recent financing will enable the company to continue advancing its lead programs through clinical studies. Financial and operating metrics beyond the recent round were not disclosed in the article.
Team
No current team members are available.